Roche Celebrates 30th Anniversary in China with Grand Opening at CIIE 2023, Showcasing Innovative Pipeline

11Month5Day，“2023 Roche CIIE Opening Ceremony and Roche Pharmaceuticals China 30th Anniversary Launch EventHeld in Shanghai。Cao Hongying, Standing Vice President of the China Association of Enterprises with Foreign Investment, Jin Qinxian, Dean of Beijing Tsinghua Industrial Development Research Institute, Zhou Shihua, General Manager of Xinhua Net Health Division, Bian Xin, President of Roche Pharmaceuticals China, Li Xin, Head of Roche Global Drug Development China Center, and representatives of Roche Pharmaceuticals China management team attended the event.
 

2023 Roche CIIE Opening Ceremony and Roche Pharmaceuticals China 30th Anniversary Launch Event

Cao HongyingSay，“The Association of Foreign-Invested Enterprises in China will actively play a bridging role, facilitating economic and trade cooperation as well as cultural exchanges among its members, and optimizing resource allocation. We hope that, through Swiss enterprises like Roche, we can leverage the China International Import Expo (CIIE) to promote exchanges between China and Switzerland, bringing more international innovative product solutions to China for the benefit of Chinese patients.

Bian XinSay, this year, Roche brings nearlyA Full Product Matrix of 30 Products and Innovative Solutions, Both Marketed and Upcoming, Attends the CIIE for the Sixth TimeMoreA global innovative product is about to be launched in China, covering disease areas such as ophthalmology, hematology-oncology, breast cancer, and neuroscience. Next year will mark the anniversary of Roche's pharmaceutical establishment in China.For the 30th anniversary and beyond, Roche will continue to accelerate the introduction of innovative drugs while collaborating with multiple partners to explore new cooperation models, focusing on building an innovative, collaborative, and diverse healthcare ecosystem in China.

Li XinSay，“Roche's robust product pipeline is inseparable from its substantial investment in research and development. Roche is always committed to collaborating with various parties, adhering to science, continuously making breakthroughs, and creating an increasingly diversified product pipeline while delivering these innovative solutions to patients in China and around the world to meet their unmet needs.”

Lori Long, Vice President of Corporate Affairs and Communications at Roche Pharmaceuticals China, introducedSayIn addition to showcasing global innovative products and cutting-edge technologies, Roche will also host multiple product launches. Furthermore, the exhibition booth features interactive, digital, and tech-savvy experiential installations, including personalized healthcare.3D Experience Center, including interactive experience spaces such as a convenient injection experience module for breast cancer patients, an anti-influenza interactive area, and a demonstration device for the mechanism of action in hematological tumors, immersively showcasing Roche's innovative achievements.

At the CIIE，Brought by RocheMultipleInnovative Products:Intravitreal injection of bispecific antibody Faricimab (Faricimab), its innovative mechanism can extend the drug's duration of action, stabilize blood vessels and reduce fluid leakage, thereby improving patients' vision.；Ocrelizumab, a drug used for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis (Ocrelizumab）；TargetedGlofitamab, an innovative bispecific antibody targeting CD20 and CD3；For the treatment of paroxysmal nocturnal hemoglobinuria (Crovalimab, an innovative drug for PNH, was granted priority review status by the National Medical Products Administration last year, after being designated as a breakthrough therapy.；Anti-Breast CancerHER2 Dual-Target Subcutaneous Compound Formulation Phesgo，This is the first time Roche has combined two monoclonal antibodies, which can be administered via a single subcutaneous injection, significantly reducing administration time (only requiring...5-8 minutes), providing patients with a faster, less invasive new treatment option.